Company: BIAF
Filing Date: 2025-10-09
Form Type: 424B5
Source: 0001493152-25-017591
Chunk: 13

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-10-09
Form: 424B5
Chunk 13
---
 1.34 |   |
| Dilution per share to the new investor in this offering                                         |     | $ |  1.19 |   |

The number of shares of common stock to be outstanding immediately after this offering is based on 948,651 shares of common stock outstanding as of June 30, 2025, and excludes, as of such date:

| ● | 939,680                                                                                                                            
 shares of common stock issuable upon the exercise of outstanding warrants with a weighted average exercise price equal to $41.60   
 per share;                                                                                                                         |
| ● | 9,530                                                                                                                              
 shares of common stock issuable upon the exercise of stock options issued under our equity incentive plans with a weighted average 
 exercise price equal to $207.30 per share; and                                                                                     |
| ● | 41,908                                                                                                                             
 shares of our common stock that are reserved for equity awards that may be granted under our 2024 Equity Incentive Plan.           |

| S-7 |

<div align='center'>PLAN OF DISTRIBUTION</div>

WallachBeth has agreed to act as the exclusive placement agent for us in connection with this offering, subject to the terms and conditions of the placement agency agreement dated October 8, 2025. WallachBeth is not purchasing or selling any of the shares of our common stock offered by this prospectus supplement, nor are they required to arrange the purchase or sale of any specific number or dollar amount of shares of our common stock, but WallachBeth has agreed to use its reasonable best efforts to arrange for the sale of all of the shares of our common stock offered hereby. Therefore, we have entered into the securities purchase agreements directly with investors in connection with this offering, and we may not sell the entire amount of shares of our common stock offered pursuant to this prospectus supplement. We made offers only to a limited number of institutional accredited investors.

We have agreed to indemnify WallachBeth against specified liabilities, including liabilities under the Securities Act, and to contribute to payments WallachBeth may be required to make in respect thereof.

Fees and Expenses

We have agreed to pay WallachBeth a placement agent fee equal to 8.0% of the aggregate purchase price of the shares of our common stock sold in this offering. The following table shows the per share and total cash placement agent fees we will pay to WallachBeth in connection with the sale of the shares of our common stock offered pursuant to this prospectus supplement and the accompanying prospect